Efficacy and Safety of Abbreviated Eptifibatide Treatment in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

•Eptifibatide mediates potent antithrombotic effects when used in primary PCI. •Standard eptifibatide infusion for several hours increases bleeding complications. •A novel, short regimen retains ischemic protection during •Bleeding complications are greatly reduced by the abbreviated regimen. •Avoiding prolonged treatment may improve clinical outcomes. The glycoprotein IIb/IIIa inhibitor eptifibatide, administered as bolus followed infusion, is an adjunctive percutaneous coronary intervention (PCI) selected patients with ST-segment elevation myocardial infarction (STEMI). Whether both and necessary to outcomes unknown. We hypothesized that PCI only non-inferior conventional (bolus infusion) regard infarct size, while reducing analyzed 720 consecutive STEMI receiving or observational case-control study utilizing propensity score matching of intervention-specific confounders. Infarct size was estimated based on bound creatine kinase, kinase (CK), CK area under curve values, a prespecified non-inferiority margin 20%. Major defined type 2, 3, 5 Bleeding Academic Research Consortium classification. Eptifibatide 147 (20%), which were matched 1:1 treatment. Based peak −8.4% (95% CI [−31.2%, 14.4%]), −11.6% [−33.5%, 10.3%]), −13.9% [−34.1%, 6.2%]) after bolus, respectively, reaching noninferiority compared Bolus significantly major (OR 0.48, 95% [0.30, 0.79]). In conclusion, given who underwent noninferior regarding resulted less